Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 2011. The report details a specific share repurchase transaction executed on July 28, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 850,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,387.5 pence per share; lowest price paid was 1,351.5 pence per share.
- Treasury Holdings (Settled): 493,104,284 shares (8.80% of total issued share capital).
- Treasury Holdings (Including Unsettled): 496,646,816 shares (9.72% of total voting rights).
- Shares in Issue: 5,111,599,613 shares (excluding treasury shares).
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 850,000 shares. Consequently, the Company's treasury holdings increased to represent 8.80% of total issued share capital, with total voting rights held in treasury reaching 9.72% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. The stated intent is to hold the purchased shares in Treasury.
Investor Verification Checklist
- Verify the total number of shares in issue (5,111,599,613) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the current percentage of voting rights held in Treasury (9.72% including unsettled shares).
- Review the price range paid (1,351.5 to 1,387.5 pence) against market prices on July 28, 2011.
- Note that this filing does not contain financial performance data; refer to Form 20-F for comprehensive financial statements.